logo
Share SHARE
FONT-SIZE Plus   Neg

Forest Labs' Unit To Acquire Royalties For Bystolic From Janssen Pharmaceutica

Forest Laboratories Inc (FRX) Monday revealed that its wholly-owned subsidiary unit, Forest Laboratories Holdings Limited, has entered into a definitive agreement with Janssen Pharmaceutica NV, wherein the subsidiary unit will acquire all U.S. patents and other U.S. and Canadian intellectual property for Bystolic (nebivolol), which is currently approved in the United States for the treatment of hypertension.

FRX revealed that its subsidiary unit has agreed to make a one-time cash payment of $357 million to Janssen Pharmaceutica NV, and, in turn, Janssen Pharmaceutica will assign all U.S. patents and other U.S. and Canadian know-how covering Bystolic, including the nebivolol composition of matter patent in the U.S. to the subsidiary unit of FRX.

The company further revealed that the subsidiary unit will amortize the one-time cash payment over the remaining patent life of Bystolic.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Seattle police caught an alleged car thief by remotely locking him inside the stolen BMW 550i with the help of the automaker. The Seattle Police Department said in its blog that the incident took place in Seattle in November. United Airlines' new ticket option called 'Basic Economy,' which would require travelers to pay extra fees for using overhead bins, has been termed by New York Senator Charles Schumer as "one of the most restrictive policies on airline passengers seen in a long time." Schumer said that United Airlines should scrap its plan. United Airlines' new ticket option called 'Basic Economy,' which would require travelers to pay extra fees for using overhead bins, has been termed by New York Senator Charles Schumer as "one of the most restrictive policies on airline passengers seen in a long time." Schumer said that United Airlines should scrap its plan.
comments powered by Disqus
Follow RTT